Home>Topics>>Therapeutic Proteins Offer New Investment Opportunities

Therapeutic Proteins Offer New Investment Opportunities

Healthcare Sector and Stocks Analysis from Seeking Alpha

Sat, 24 Nov 2012

By Cris Frangold : A few days ago, Prolor Biotech ( PBTH ) was downgraded by research analysts at Summer Street from a "buy" rating to a "sell" rating. Summer Street now has a $3.00 target price on the stock, down from their previous target price of $6.00. The stock is trading at around $4.42 with ...

Related Videos

  1. No Sign of Slowdown in Biotech M&A

    Tue, 10 May 2011

    High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.

  2. Top Biotech Acquisition Candidates

    Thu, 5 Apr 2012

    2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.

  3. Our Top Five Biotech Takeout Picks

    Fri, 26 Feb 2010

    Health-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.

  4. Our Top Five Biotech Acquisition Candidates

    Thu, 17 Mar 2011

    M&A activity grew in 2010, and we expect deal volume to remain strong in 2011.

Content Partners